Bioenergy, Inc. is an integrated biotechnology company with a mission to develop products to improve our daily lives. Our core technology centers on the pentose carbohydrate, ribose, and the dramatic metabolic impact it has on restoring energy. Ribose amplifies the body's natural response to metabolic stress, helping to regenerate energy when tissues are stressed, such as with cardiovascular diseases. Patients afflicted with compromised heart function find that ribose allows them to do more and enjoy a higher quality of life. For healthy people, ribose can also provide needed energy, reflected in less fatigue, greater exercise performance over time, and faster energy recovery following exercise. No other compound plays such an important metabolic role in our body. Bioenergy, Inc. manufactures and commercializes various ribose-based products that transcend a spectrum from nutraceuticals to medical foods to pharmaceuticals. Our branded nutraceutical and medical food products provide metabolic support to stressed tissue, including hearts and skeletal muscles. Our bioactive ingredient, Bioenergy RIBOSE, is widely used in foods and beverages as an energy enhancing nutraceutical, accelerating energy recovery and decreasing fatigue. The Company's pharmaceutical division centers on the use of ribose in chronic diseases, such as heart disease, and our cutting edge cell technology solutions are designed to improve transfusable blood products.

Bioenergy Life Science, Inc.

Bioenergy Life Science, Inc. focuses on using the energetic science of D-ribose to fuel a range of all-natural nutritional products. Decades of scientific and clinical research has shown that ribose improves energy recovery, and we have drawn on this research in our nutraceutical foods, beverages, and clinical nutritional products. Bioenergy Life Science has relationships with many of the world's leading companies and is dedicated to energizing their active lifestyle products. Additionally, Bioenergy Life Science, Inc. has partnered with hospitals, medical clinics, and healthcare professionals to bring the power of ribose to patients through its proprietary family of clinical nutritional products.

Bioenergy Pharmaceuticals
Bioenergy Pharmaceuticals is a separate division in Bioenergy, Inc. developing infusible pharmaceuticals for both diagnostic and therapeutic applications in medicine, presently focusing in the area of cardiovascular medicine.
Viacell, LLC Technology
The world faces a continual shortage of blood products, which threatens the health of patients worldwide. A solution to this problem centers on techniques that will extend the useful storage life of blood components while preserving cell function. Viacell has developed ribose-based additive solutions to extend and maintain function of preserved blood products. One developed solution, when added to harvested platelets, extends storage life and preserves viability and function. Platelets help to form clots and aid in controlling bleeding. Viacell also has developed an additive solution that aids with normal storage and rejuvenation of red blood cells to maintain the intracellular component necessary for oxygen transport, key for tissue survival and function.


Bioenergy, Inc. Executive Management
Sharing the Vision

Bioenergy, Inc. has assembled an experienced management team with the single vision of improving lives. Executives and scientists knowledgeable in nutrition, pharmaceuticals, business development, and operations have come together to discover, develop, and distribute important products affecting the energy health and wellness of millions worldwide.

Raj Khankari, PhD, MBA

Chief Executive Officer

Raj Khankari, PhD joined Bioenergy, Inc. in August 2008. Dr. Khankari comes from CIMA Labs Inc., a Cephalon company, where he served as General Manager, CIMA Labs Inc., and Vice President for Worldwide Drug Delivery Technologies. Dr. Khankari earned his initial degrees in Pharmaceutics from universities in India. Dr. Khankari also has a PhD in Pharmaceutics and an MBA from the University of Minnesota. In addition to holding several patents, Dr. Khankari has been widely published in several peer reviewed journals and has been a presenter at more than two dozen national and international meetings.

Ross Boerhave

Vice President Operations

Ross Boerhave has been with the Company since its inception. From 1985 to 1995 he served as vice president of the Minnesota Cooperation Office (MCO), a non-profit corporation established to assist start-up companies. Prior to joining MCO, Mr. Boerhave spent three years as treasurer for The EntreSource Companies, a Minneapolis-based investment banking firm. Additionally, Mr. Boerhave has held various positions with the Resource Companies, Inc. and Bremer Service Company. He currently serves on the boards of directors of two privately held companies. Mr. Boerhave graduated from St. Cloud State University with a B.Sc. in Finance and honors in Liberal Studies.

Thomas VonderBrink

President
Bioenergy Life Science, Inc.

Tom VonderBrink joined Bioenergy in January 2000 and became president and chief operating officer of its Bioenergy Life Science subsidiary in 2003. VonderBrink is responsible for managing Bioenergy Life Science operations, focused on general and clinical nutrition. VonderBrink has vast experience in clinical nutrition product development, sales, marketing and operations management. Before joining Bioenergy, he spent 25 years with Novartis Corporation (formerly Sandoz, Inc.) where he began his career as sales representative in 1974 before evolving through increasingly responsible management positions. His most recent role at Novartis was general manager responsible for senior care, health systems and trade market segments where he managed more than $800 million in contracted sales. After receiving an undergraduate degree in psychology from Thomas Moore College in Fort Mitchell, KY, VonderBrink went on to earn a masters degree in counseling and guidance from Xavier University, Cincinnati, OH.

Bioenergy Board of Directors and Advisors

John Broadbent, Chairman, was a co-founder of Arrow International, Inc., a leading developer, manufacturer and worldwide marketer of a broad range of clinically advanced, disposable catheters and related products for critical and cardiac care. Mr. Broadbent was Chief Financial Officer of Arrow from 1975 to 1998 and a Director of Arrow from its founding in 1975 until the Company was acquired in 2007. Mr. Broadbent earned a bachelor's degree in chemical engineering from Rensselaer Polytechnic Institute, where he has been a Trustee since 1995, and a MBA from Harvard University. He is an investor in several privately held companies in the healthcare field.

Helmut Breuer is retired chairman of the Lombard Odier Nutrition Fund Advisory Board, Zurich, Switzerland. From 1992 to his retirement in 1997, he was vice president and director of Sandoz Nutrition Ltd/Novartis Nutrition Corp, Berne, Switzerland, where he had global responsibility for the medical nutrition and infant nutrition businesses. From 1976 to 1992 he held several executive positions for Sandoz Nutrition in Minneapolis, Minnesota. In 1984 he was appointed president and ceo of Sandoz Nutritions US operations that included clinical nutrition, health food services, and hospital based weight management programs. Mr. Breuer held this position until his transfer to Switzerland in 1992.

Howard Weintraub, Ph.D. is a principal of the Landfall Therapeutics Consulting Group, LLC, which provides strategic and technical consulting for pharmaceutical and medical device companies. Until his retirement in 2003, Dr. Weintraub was Vice President, R & D Corporate Staff for C.R. Bard. In this role, Dr. Weintraub was responsible for providing oversight to Bards research and development groups and managing identification and selection of new technology and product opportunities for the company. Dr. Weintraub received a B.Sc. in Pharmacy from Columbia before completing a Ph.D. in biopharmaceutics from the State University of New York, Buffalo. He has over 35 years experience in pharmaceutical research and development.

Tito Weiss is senior financial advisor to the Adventist Health System/Sunbelt Healthcare Corporation. Until his retirement in 1997 Mr. Weiss was vice president and CFO for Sunbelt Home Health Care, Inc., a subsidiary of AHS, where he managed financial affairs for ten hospital-based agencies in excess of 1 million visits per year. Mr. Weiss has held senior executive positions at AHS since 1987, including a position as senior vice president, Florida Hospital and CFO and chairman of the Hospital finance committee, Florida Hospital Cluster (four hospitals). Mr. Weiss holds a BA in Commerce from River Platte College, Argentina. Mr. Weiss is also chairman of the companys audit committee.

H.B. Bud Hayden is founder and former principal shareholder of Metro-quip, Inc., a Minnesota-based Midwest distributor of construction equipment. Mr. Hayden, a well-known Twin Cities entrepreneur, joined the Bioenergy board of directors in 1996. He served as the companys interim CEO from May 2007 through July 2008. Mr. Hayden earned a bachelors degree in mechanical engineering from the Sibley School of Mechanical Engineering, College of Engineering, Cornell University.

Danielle Johnson currently holds the position of Assistant Vice President and administrator of the Cardiovascular Institute at Florida Hospital. In this role she is responsible for the strategic planning, financial management, and daily operations of the Cardiovascular Service Line encompassing 228 inpatient licensed beds, forty eight observation beds, Perfusion Services, twelve Cardiac Catheterization laboratories — located across five campuses, Echo, ECG and stress — across seven campuses, four EPS labs, CV Registry department, outpatient Heart Failure Clinic and a comprehensive Cardiac Research division. Nursing was her primary healthcare training which led to positions in critical care, organ donation services and quality management.

Mr. Shengping Xu is the founder of Desano Group, which was established in 1996 and is dedicated to the R&D, manufacturing and marketing of pharmaceutical products and nutritional ingredients. The business scope includes pharmaceutical intermediate, APIs and finished products of Antiretroviral, Antimalarial, Oncology, Gynecology and Monoclonal Antibody drugs. He was granted Bachelor Degree in Chemistry and Economy in 1994 by Nan Kai University.

Raj Khankari, PhD, MBA became the Chief Executive Officer of Bioenergy, Inc. in August 2008. Dr. Khankari joined the company from CIMA Labs Inc., a Cephalon company, where he served as General Manager, CIMA Labs Inc., and Vice President for Worldwide Drug Delivery Technologies. Dr. Khankari earned his initial degrees in Pharmaceutics from universities in India. Dr. Khankari also has a PhD in Pharmaceutics and an MBA from the University of Minnesota. In addition to holding several patents, Dr. Khankari has been widely published in several peer reviewed journals and has been a presenter at more than two dozen national and international meetings.

Ross Boerhave has been with the Bioenergy, Inc. since its inception and is currently the Vice President of Operations. From 1985 to 1995 he served as vice president of the Minnesota Cooperation Office (MCO), a non-profit corporation established to assist start-up companies. Prior to joining MCO, Mr. Boerhave spent three years as treasurer for The EntreSource Companies, a Minneapolis-based investment banking firm. Additionally, Mr. Boerhave has held various positions with the Resource Companies, Inc. and Bremer Service Company. He currently serves on the boards of directors of two privately held companies. Mr. Boerhave graduated from St. Cloud State University with a B.Sc. in Finance and honors in Liberal Studies.


 


.